Browsing Tag
Multiple myeloma
44 posts
Aurobindo Pharma subsidiary receives FDA approval for Plerixafor Injection
Eugia Pharma Specialities Limited, a fully-owned subsidiary of India-based Aurobindo Pharma Limited, has received final approval from the…
July 25, 2023
Legend Biotech announces submission of CARVYKTI application to EMA for multiple myeloma
Legend Biotech has announced the submission of a Type II variation application to the European Medicines Agency (EMA)…
May 28, 2023
LaNova Medicines, AstraZeneca sign $600m worth licensing deal for LM-305
LaNova Medicines has signed an exclusive license deal worth over $600 million for its pre-clinical stage antibody drug…
May 14, 2023
Natco Pharma completes full US generic Revlimid lineup with new lenalidomide strengths
Natco Pharma and Teva Pharmaceuticals launch 2.5 mg and 20 mg generic lenalidomide in US, completing their Revlimid portfolio for multiple myeloma treatment.
March 12, 2023
Arcellx, and Kite to jointly advance CART-ddBMCA for multiple myeloma
Arcellx, a US-based clinical-stage biotechnology company, and Kite, a Gilead company, are partnering to co-develop and co-commercialize the…
December 13, 2022
Thermo Fisher to buy specialist protein diagnostics company Binding Site
Thermo Fisher Scientific has agreed to acquire The Binding Site Group, a UK-based specialist protein diagnostics company, for…
November 1, 2022
FDA approves Janssen’s TECVAYLI for multiple myeloma treatment
The Janssen Pharmaceutical Companies, a subsidiary of Johnson & Johnson, announced the US Food and Drug Administration’s approval…
October 27, 2022
Zydus Lifesciences gets FDA approval for Bortezomib for Injection
Zydus Lifesciences (previously called Cadila Healthcare) said that it has secured final approval from the US Food and…
May 3, 2022
GSK to acquire US biopharma company Sierra Oncology for $1.9bn
GlaxoSmithKline (GSK) has agreed to acquire Sierra Oncology, a California-based biopharma company, in a deal worth around $1.9…
April 23, 2022
Harpoon Therapeutics gets FDA fast track status for HPN217 in RRMM
Harpoon Therapeutics has bagged fast track designation for HPN217 from the US Food and Drug Administration (FDA) for…
March 5, 2022